Navigation Links
Sundia's Animal Facility Passed Client and Government Inspection
Date:6/16/2009

SHANGHAI, June 16 /PRNewswire-Asia/ -- Sundia MediTech Company, a Shanghai-based integrated pharmaceutical contract research company, announced today that its animal facility in Shanghai has passed the audit from a major European Pharmaceutical Company. The Sundia management and staff are praised for providing good facilities and programs for the care and use of laboratory animals.

The inspection and audit took place in May. The entire animal facility and life studies were inspected and audited. As stated in its official approval letter: "Our overall impression of Sundia is very positive. The personnel handling animals are well trained and engaged. All procedures are well described in SOPs, and the site is very well organized." As a result of an extensive on-site evaluation, the major European pharmaceutical company determined that Sundia MediTech animal facility is committed to the highest level of animal care and research practices.

Sundia has strong institutional commitment to the animal care and use program. The Institutional Animal Care and Use Committee (IACUC) is led by CEO, Dr. Xiaochuan Wang. The state-of-art animal facility was designed by SinoPharma Group Wuhan Institute. The operation of the animal facility has followed the extensive Standard Operating Procedures (SOP) and guidelines, and all records are well maintained. The animal facility was evaluated by Shanghai Animal Management Committee, and the Permit for Using Laboratory Animals was obtained in January this year.

"The success of passing the audit demonstrated our effort to provide quality animal care for pharmaceutical research," said Dr. Jun Wang, Vice President of Biology at Sundia MediTech. "We are very pleased to receive such high praise from the leading major pharmaceutical company on the care and use of laboratory animals. It demonstrates the quality of our laboratory testing and the competence of our technicians," commented Dr. Xiaochuan Wang, CEO of Sundia.

About Sundia MediTech.

Sundia MediTech is a leading integrated pharmaceutical contract research organization (CRO) company. As a customer-focused company, Sundia MediTech provides integrated drug discovery service to more than 80 top pharmaceutical companies worldwide, ranging from early hit screening, biological service, lead optimization, DMPK, candidate preclinical development, API manufacturer, regulatory submission. For more information, please visit http://www.sundia.com .


'/>"/>
SOURCE Sundia Meditech Company, Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
2. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
3. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
4. Odyssey Thera Granted U.S. Patent for Animal Imaging
5. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
6. Researchers use magnetism to target cells to animal arteries
7. Smithfield Foods, Inc. Statement Regarding Animal Cloning
8. Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally
9. Animal Protection Groups Condemn FDAs Endorsement of Animal Cloning
10. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
Breaking Biology Technology:
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Biology News(10 mins):